The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine

Neuropsychopharmacology

Volumn 30, Issue 12, 2005, Pages 2205-2215

  Marek, Gerard J ^a,c   Martin Ruiz, Raul ^b   Abo, Allyson ^a   Artigas, Francesc ^b  

^a Yale University School of Medicine   (United States)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

5 HT2A receptors; Antidepressant; DRL 72 s; Fluoxetine; M100907; SSRIs

Indexed keywords

ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; ANTIDEPRESSANT AGENT; FLUOXETINE; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; FLUOROBENZENE; PIPERIDINE DERIVATIVE; SEROTONIN ANTAGONIST;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SCREENING; DRUG SENSITIVITY; MALE; MICRODIALYSIS; MOTIVATION; NONHUMAN; PRIORITY JOURNAL; RAT; REINFORCEMENT; ANIMAL; BRAIN LEVEL; DRUG EFFECT; DRUG POTENTIATION; EXTRACELLULAR SPACE; INSTRUMENTAL CONDITIONING; METABOLISM; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BRAIN CHEMISTRY; CONDITIONING, OPERANT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; EXTRACELLULAR SPACE; FLUOROBENZENES; FLUOXETINE; MALE; MICRODIALYSIS; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A; REINFORCEMENT SCHEDULE; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS;

EID: 27844601627     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300762     Document Type: Article

References (55)

1. Adell A, Artigas F (1998). A microdialysis study of the in vivo release of 5-HT in the median raphe nucleus of the rat. Br J Pharmacol 125: 1361-1367.
2. Aghajanian GK, Marek GJ (1997). Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacology 36: 589-599.
3. 2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release. Brain Res 825: 161-171.
4. 2a receptors in pyramidal neurons of prefrontal cortex. Cereb Cortex 14: 281-299.
5. 1A receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience 40: 399-412.
6. 2A receptors in the rat medial prefrontal cortex: an iontophoretic study. Synapse 17: 173-181.
7. Borsini F (1995). Role of the serotonergic system in the forced swimming test. Neurosci Biobehav Rev 19: 377-395.
8. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC et al (1996). Radioceptor binding profile of the atypical antipsychotic olazepine. Neuropsychopharmacology 14: 87-96.
9. Cousins MS, Seiden LS (2000). The serotonin-1A receptor antagonist WAY-100635 modifies fluoxetine's antidepressant-like profile on the differential reinforcement of low rates 72-s schedule in rats. Psychopharmacology 148: 438-442.
10. Delgado PL, Charney DS, Price LH, Aghajanian GK, Landis H, Heninger GR (1990). Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 47: 411-418.
11. Delgado PL, Miller HL, Salomon RM, Licinio J, Krystal JH, Moreno FA et al (1999). Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. Biol Psychiatry 46: 212-220.
12. Hervas I, Artigas F (1998). Effect of fluoxetine on extracellular 5-hydroxytryptamine in rat brain. Role of autoreceptors. Eur J Pharmacol 358: 9-18.
13. Hirose S, Ashby CRJ (2002). An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy. J Clin Psychiatry 63: 733-736.
14. Jakab RL, Goldman-Rakic PS (1998). 5-HT2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogens in pyramidal cell apical dendrites. Proc Natl Acad Sci USA 95: 735-740.
15. Jakab RL, Goldman-Rakic PS (2000). Segregation of serotonin 5-HT2A and 5-HT3 receptors in inhibitory circuits of the primate cerebral cortex. J Comp Neurol 417: 337-348.
16. Kapur S, Zipursky RB, Remington G (1999). Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 156: 286-293.
17. 2A antagonist with a favorable CNS safety profile. J Pharmacol Exp Ther 277: 968-981.
18. Lakoski JM, Aghajanian GK (1985). Effects of ketanserin on neuronal responses to serotonin in the prefrontal cortex, lateral geniculate and dorsal raphe nucleus. Neuropharmacology 24: 265-273.
19. Luttinger D, Freedman M, Hamel L, Ward SJ, Perrone M (1985). The effects of serotonin antagonists in a behavioral despair procedure in mice. Eur J Pharmacol 107: 53-58.
20. Marcoli M, Maura G, Munari C, Ruelle A, Raiteri M (1999). Pharmacological diversity between native human 5-HT1B and 5-HT1D receptors sited on different neurons and involved in different functions. Br J Pharmacol 126: 607-612.
21. Marek GJ (2000). A novel approach to the identification of psychiatric drugs: serotonin-glutamate interactions in the prefrontal cortex. CNS Drug Rev 6: 205-217.
22. 2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. Neuropsychopharmacology 28: 402-412.
23. Marek GJ, Li AA, Seiden LS (1989). Selective 5-hydroxytryptamine2 antagonists have antidepressant-like effects on differential-reinforcement-of- low-rate 72-second schedule. J Pharmacol Exp Ther 250: 52-59.
24. Marek GJ, McDougle CJ, Price LH, Seiden LS (1992). A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action. Psychopharmacology 109: 2-11.
25. Marek GJ, Seiden LS (1988). Effects of selective 5-hydroxytryptamine-2 and nonselective 5-hydroxytryptamine antagonists on the differential- reinforcement-of-low-rate 72-second schedule. J Pharmacol Exp Ther 244: 650-658.
26. Marek GJ, Seiden LS (1994). Antidepressant drug screens and the serotonin system. In: Palomo T, Archer T (eds). Strategies for Studying Brain Disorders: Depressive, Anxiety and Drug Abuse Disorders. Vol 1. Farrand Press: London. pp 23-40.
27. Marek GJ, Wright RA, Gewirtz JC, Schoepp DD (2001). A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in neocortex. Neuroscience 105: 113-126.
28. Martin JR, Bos M, Jenck F, Moreau J, Mutel V, Sleight AJ et al (1998). 5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential. J Pharmacol Exp Ther 286: 913-924.
29. 1D receptors. Br J Pharmacol 123: 45-50.
30. 2A receptors in the middle layers of the rat prelimbic prefrontal cortex. Neuroscience 116: 107-117.
31. Murphy GMJ, Kremer C, Rodriques HE, Schatzberg AF (2003). Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 160: 1830-1835.
32. O'Connor M, Silver H (1998). Adding risperidone to selective serotonin reuptake inhibitor improves chronic depression. J Clin Psychopharmacol 18: 89-90.
33. O'Donnell JM, Marek GJ, Seiden LS (2005). Antidepressant effects assessed using behavior maintained under a differential-reinforcement-of-low-rate (DRL) operant schedule. Neurosci Biobehav Rev (in press).
34. O'Donnell JM, Seiden LS (1982). Effects of monoamine oxidase inhibitors on performance during differential reinforcement of low response rate. Psychopharmacology 78: 214-218.
35. Ostroff RB, Nelson JC (1999). Risperidone augmentation of SSRIs in major depression. J Clin Psychiatry 60: 256-259.
36. Pandey GN, Dwivedi Y, Rizavi HS, Ren X, Pandey SC, Pesold C et al (2002). Higher expression of 5-HT2A receptors in the postmortem brains of teenage suicide victims. Am J Psychiatry 159: 419-429.
37. Paxinos G, Watson C (1986). The Rat Brain in Stereotoxic Coordinates. Academic Press: Orlando, FL.
38. Pericic D (2003). Swim stress inhibits 5-HT2A receptor-mediated head twitch behavior in mice. Psychopharmacology 167: 373-379.
39. Peroutka SJ, Snyder SH (1980). Long-term antidepressant treatment decreases spiroperidol-labeled serotonin receptor binding. Science 210: 88-90.
40. 2A receptors. Relationship to thalamocortical afferents. Cereb Cortex 13: 870-882.
41. Puller IA, Carney SL, Colvin EM, Lucaites VL, Nelson DL, Wedley S (2000). LY367265, an inhibitor of the 5-hydroxytryptamine transporter and 5-hydroxytryptamine 2A receptor antagonist: a comparison with the antidepressant, nefazodone. Eur J Pharmacol 407: 39-46.
42. Redrobe JP, Bourin M (1997). Partial role of 5-HT2 and 5-HT3 receptors in the activity of antidepressants in the mouse forced swimming test. Eur J Pharmacol 325: 129-135.
43. Richards JB, Seiden LS (1991). A quantitative interresponse time analysis of DRL performance differentiates similar effects of the antidepressant desipramine and the novel anxiolytic gepirone. J Exp Anal Behav 56: 173-192.
44. Schmidt CJ, Fox CB, Harms JF, Wylie P, Seegar TF, Guanowsky V et al (2001). CP-646,781: a potent dual SSRI/5-HT2A receptor agonist. Socr Neurosci Abstr 27: Program no. 665-17.
45. Schotte A, Janssen PFM, Gommeren W, Luyten WH, Van Gompel P, Lesage AS et al (1996). Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124: 57-73.
46. Schreiber R, Brocco M, Audinot V, Gobert A, Veiga S, Millan MJ (1995). 1-(2,5-Dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine(5-HT)2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists. J Pharmacol Exp Ther 273: 101-112.
47. Seiden LS, Dahms JL, Shaughnessy RA (1985). Behavioral screen for antidepressants: the effects of drugs and electroconvulsive shock on performance under a differential-reinforcement-of-low-rate schedule. Psychopharmacology 86: 55-60.
48. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG et al (2001). A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 158: 131-134.
49. Sokolowski JD, Seiden LS (1999). The behavioral effects of sertraline, fluoxetine, and paroxetine differ on the differential-reinforcement-of-low-rate 72-second operant schedule in the rat. Psychopharmacology 147: 153-161.
50. Stockmeier CA, Dilley GE, Shapiro LA, Overholser JC, Thompson PA, Meltzer HY (1997). Serotonin receptors in suicide victims with major depression. Neuropsychopharmacology 16: 162-173.
51. Tanaka E, North RA (1993). Actions of 5-hydroxytryptamine on neurons of the rat cingulate cortex. J Neurophysiol 69: 1749-1757.
52. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C et al (2003). Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 60: 1079-1088.
53. Willins DL, Deutch AY, Roth BL (1997). Serotonin 5-HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex. Synapse 27: 79-82.
54. Zhang W, Perry KW, Wong DT, Potts BD, Bao J, Tollefson GD et al (2000). Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 23: 250-262.
55. Zhou F-M, Hablitz JJ (1999). Activation of serotonin receptors modulates synaptic transmission in rat cerebral cortex. J Neurophysiol 82: 2989-2999.